Key Highlights

  • Fusion Antibodies Plc (LSE:FAB) remained in focus on 16 October 2026 after its shares fell by more than 41% intraday the previous morning following a weak first-half trading and AGM update.
  • First-half revenue for the 2026/27 financial year dropped to £457,000 from £838,000 a year earlier, with gross margin sliding to about 10%.
  • Cash stood at roughly £135,000 at the end of the period, with more than £100,000 of grant funding said to be due imminently, and a recruitment freeze is now in place.
  • The board is reviewing working capital needs, and the latest annual accounts flag a material uncertainty over the company's ability to continue as a going concern.
  • Scientific progress continues, with patents for the OptiMAL platform secured in Japan and Canada, Australia close behind, and the DR5 therapeutic antibody programme producing its most promising data so far.

Why Fusion Antibodies Is in Focus on 16 October 2026

Fusion Antibodies Plc (LSE:FAB), the Belfast-based antibody specialist quoted on AIM, was closely watched on Friday 16 October 2026 after a dramatic Thursday session, when the shares dropped by more than 41% to around 5.75p in morning trade after the company issued a combined AGM statement, first-half trading update and research update.

By Friday's close the stock had settled at roughly 6.88p, down under 1% on the day, on volume about double the recent average. That gives a market capitalisation of roughly £8.6 million, with the shares near the bottom of a 52-week range whose high of 20p was set in December 2025.

What the Latest Update Revealed

The core of the sell-off was a sharp drop in first-half revenue. Fusion Antibodies reported revenue of £457,000 for the opening half of the 2026/27 financial year, compared with £838,000 in the same period a year earlier. Gross margin fell to around 10%, which the company linked to weak market conditions that have suppressed demand for outsourced antibody services.

Liquidity is the issue most investors are focused on. The company said cash at the end of the period was about £135,000, although it expects more than £100,000 in grant funding to arrive imminently. A recruitment freeze has been introduced, and the board is reviewing working capital requirements because trading has come in below expectations.

Business Background and Strategy

Fusion Antibodies provides antibody discovery and engineering services to pharmaceutical and biotechnology customers and is working to diversify beyond early-stage biotech clients, whose spending has been subdued.

A central plank of the strategy is OptiMAL, an antibody discovery platform launched in December 2025. The platform has received independent validation from the US National Cancer Institute, and negotiations on a formal agreement for the institute to screen the OptiMAL library are continuing, though management has stressed that timing remains uncertain. Intellectual property protection is widening: following a US patent granted in 2025, the company has secured patents in Japan and Canada, and Australia is close to completion.

Alongside its services business, the group is advancing a grant-funded DR5 therapeutic antibody programme with Queen's University Belfast. The latest update said this work has delivered its most promising data yet, and the company has previously indicated that it aims to have a pre-clinical asset available for partnering from late in the current financial year.

Financial Position in Context

The latest half-year numbers contrast with the full-year results for the year ended 31 March 2026, which showed revenue rising about 7% to £2.11 million and gross margin improving to 58.3% from 22% a year earlier. The operating loss narrowed to £1.13 million from a restated £1.63 million, despite higher research and development spending to validate OptiMAL. Year-end cash was £1.04 million, helped by a January 2026 placing at 13p.

However, the annual accounts also included a material uncertainty statement on going concern, noting that further funding is expected to be required and is not yet contractually committed. Chairman Simon Douglas has pointed to subdued healthcare markets and slow investment in early-stage drug development as ongoing headwinds. The steep fall in first-half revenue and the reduced cash balance make the funding question for Fusion Antibodies Plc (LSE:FAB) more pressing.

Sector and Market Backdrop

Life science service providers face a difficult funding environment, with many early-stage biotech companies conserving cash and delaying discovery programmes, which leaves smaller service businesses with lumpy order books and margin pressure. AIM investors have become highly sensitive to cash runway in this environment.

Risks to Consider

The most immediate risk for Fusion Antibodies Plc (LSE:FAB) is funding. With cash in the low hundreds of thousands of pounds and a going concern uncertainty already disclosed, any new capital raise at current share prices could be significantly dilutive. Revenue visibility is limited. Commercialisation of OptiMAL may take longer than hoped, and the National Cancer Institute agreement is not yet signed.

What Investors Are Watching Next

Attention will now turn to how the board addresses working capital, including the receipt of expected grant income and any decision on new funding. Investors will look for signs of improving order intake in the second half, progress toward a signed agreement with the National Cancer Institute, completion of the Australian patent, and any partnering interest in the DR5 programme. Given the share price reaction, any update on cash runway from Fusion Antibodies Plc (LSE:FAB) is likely to carry particular weight.